Ashley Grossman
Ashley Grossman
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [0.03%]
达格列净对有或无2型糖尿病的慢性肾脏病患者肾功能下降速率的影响：DAPA-CKD试验的预设分析
Hiddo J L Heerspink,Niels Jongs,Glenn M Chertow et al.
Hiddo J L Heerspink et al.
Background: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagl...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Nov;9(11):743-754. DOI:10.1016/S2213-8587(21)00242-4 2021
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial [0.03%]
在DAPA-CKD试验期间通过尿蛋白和eGFR斜率预测治疗反应
Katherine R Tuttle
Katherine R Tuttle
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [0.03%]
达格列净对伴有或不伴有2型糖尿病的慢性肾病患者尿白蛋白排泄的影响：DAPA-CKD试验的预设分析
Niels Jongs,Tom Greene,Glenn M Chertow et al.
Niels Jongs et al.
Background: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients ...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Nov;9(11):755-766. DOI:10.1016/S2213-8587(21)00243-6 2021
Charlotte Steenblock,Peter E H Schwarz,Barbara Ludwig et al.
Charlotte Steenblock et al.
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction ...
Bart Van der Schueren,Darcy Ellis,Raquel N Faradji et al.
Bart Van der Schueren et al.
Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hy...
Statins for Graves' orbitopathy: a new tool for prevention and treatment? [0.03%]
他汀类药物治疗格雷夫眼病：一个新的预防和治疗方法？
Luigi Bartalena,Eliana Piantanida,Maria Laura Tanda
Luigi Bartalena
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial [0.03%]
他汀类药物治疗格雷夫眼病（STAGO）：一项二期、无盲法、适应性、单中心随机临床试验
Giulia Lanzolla,Elena Sabini,Marenza Leo et al.
Giulia Lanzolla et al.
Background: A protective action of statins on development of Graves' orbitopathy suggests that statins might be used for treatment of the disease. We aimed to assess the efficacy of the addition of a statin, atorvastatin,...